Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions

被引：1
|
作者：
Goldberg, R. [1 ]
Beswick, L. [2 ]
Van Langenberg, D. [3 ]
Sally, B. [4 ,5 ]
Rosella, O. [2 ]
Gibson, P. [2 ]
Moore, G. [1 ]
机构：
[1] Monash Univ, Monash Hlth, Dept Gastroenterol, Melbourne, Vic 3004, Australia
[2] Alfred Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60498-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P378
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 50 条
  • [21] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [22] Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment
    Patil, Abhishek
    Upadhyaya, Sundeep
    Dawar, Reetika
    Dadhaniya, Nikunjkumar
    Sood, Isha
    Gupta, Sirinder J.
    Handa, Rohini
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1638 - 1643
  • [23] Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD
    Jelk, D.
    Perreau, M.
    Michetti, P.
    Maillard, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S410 - S410
  • [24] The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-α levels and clinical outcome
    Bodini, G.
    Savarino, V.
    Dulbecco, P.
    Baldissarro, I.
    Savarino, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S42 - S42
  • [25] REAL-LIFE INFLIXIMAB AND ADALIMUMAB TROUGH LEVEL AND ANTI-DRUG ANTIBODY MEASUREMENTS IN RHEUMATOLOGY: THE FINNISH EXPERIENCE
    Ho, D.
    Valtanen, S.
    Havana, M.
    Kroger, L.
    Eklund, K.
    Jokiranta, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 827 - 827
  • [26] PERSONALISING CARE: USING INFLIXIMAB DRUG TROUGH AND ANTI-DRUG ANTIBODY LEVELS IMPROVES CLINICAL TREATMENT DECISIONS AND IS A COST EFFECTIVE STRATEGY IN SPONDYLOARTHRITIS
    Dubash, S.
    Bryer, D.
    Fitton, J.
    Barr, A.
    Vandevelde, C.
    Marzo-Ortega, H.
    Freeston, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1551 - 1552
  • [27] Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS™, Infliximab-abda) Using LabCorp Infliximab Assays for Drug Level and Anti-drug Antibodies
    Kelly, Chun
    Zonia, Garcia Gonzalez
    Jane, Yang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S25 - S25
  • [28] Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
    Berger, Anne Emmanuelle
    Gleizes, Aude
    Waeckel, Louis
    Roblin, Xavier
    Krzysiek, Roman
    Hacein-Bey-Abina, Salima
    Soriano, Alessandra
    Paul, Stephane
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [29] Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
    Karsten, Carley
    Grannas, Karin
    Bergman, Oskar
    Moverare, Robert
    Roforth, Matthew
    Willrich, Maria Alice V.
    Snyder, Melissa R.
    Yang, Yifei K.
    [J]. AAPS JOURNAL, 2024, 26 (05):
  • [30] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
12345